The US Environmental Protection Agency, under 2 of its legislative mandates, has the authority to require the testing of industrial and pesticide chemicals. Among the testing requirements, particularly in chronic studies, are those relating to hematology, clinical chemistry, and urinalysis. Some of these requirements will be discussed in detail. Comments on the usefulness of the current requirements and recommendations for changes will be solicited from the meeting participants.
This is a propitious time to be discussing the subject of clinical pathology for our Division of the US Environmental Protection Agency (EPA) . The EPA has the responsibility for administering about a dozen environmental statutes. Of those, 2 provide testing authority: the Toxic Substances Control Act (TSCA) and the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA). TSCA covers industrial chemicals and FIFRA covers pesticides. The requirements that are imposed under TSCA tend to be done by regulation. For example, when the Office of Pollution Prevention and Toxics wishes to require testing on a chemical, they must write a regulation. In other words, the onus is, in essence, on the Agency to prove or disprove safety. Under FI-FRA, the opposite is true; the sponsor of the chemical must prove a priori that the chemical is safe for the use intended.
Two current Agency initiatives make today's discussion very pertinent. The EPA, in general, is becoming much more involved in the international community, whether it be on scientific, regulatory, or political issues. Our administrator is very interested in our playing a much more significant role in environmental quality on the global level. Within the purview of my office, the Office of Pollution, Pesticides and Toxic Substances, one of those global arenas is the testing of chemicals of all kinds.
Within the agency, we also are participating in a guidelines harmonization project. The guidelines were originally written in harmony, but over the last decade there has been a modest divergence, in some cases. So the goal for us is to put our house in order and have the guidelines that we develop for testing under TSCA be compatible with those for testing under FIFRA. Given that the Pesticides office and the Toxics office are under the administration of a single assistant administrator, this can be done with relative ease.
When the internal harmonization is complete, our second goal is to have our guidelines be in harmony with the international community as represented by the Organization for Economic Cooperation and Development (OECD) guidelines for chemicals. This effort is becoming more complicated because of the potential for the European Communities (EC) to develop some of its own guidelines separate from OECD. In recent weeks, we have received word from the EC Directorate of the Environment, who is responsible for industrial chemicals, that they will adopt OECD testing guidelines rather than creating their own. We have not yet received similar assurance from the EC Directorate of Agriculture, who is responsible for pesticide regulation, that they might or might not do the same.
Within the United States, the guidelines of the various government agencies are not necessarily identical, although in many cases thev are similar; therefore, there is also a need to work toward putting our Federal house in order.
We in the EPA do not ask for human data. Our FIFRA Scientific Advisory Panel has on occasion suggested we do, but we are disinclined. We have virtually total dependence in our risk assessment process upon data generated in animal studies. Therefore, when animal testing is done, we have 2 goals in mind: (1) making use of the animal data to understand fully the toxicological profile of the agent of interest and (2) using that information to determine the nature and magnitude of any human health risk that might ensue should exposure to that chemical agent occur, under whatever circumstances.
There is a distinction between the EPA and the drug side of the Food and Drug Administration in that we cannot necessarily guarantee, if exposure were to occur, how it will occur. I, personally, tend to be a minimalist when it comes to asking for data. I do not believe we should ask for data just to have data; instead we should ask for it because it will actually be of some use. I would like to see crafted testing protocols and designs that reflect the evaluation of parameters that actually provide us with some ability to understand the toxicology of the chemical of interest in the tested species and actually are predictive of human risk, as opposed to just receiving information because it is nice to have.
In September 1990, a Federal Register notice was published over my signature that invited technical comments on our Subpart F guidelines. These are the testing guidelines related to hazard evaluation for pesticides and human health. It opened up the opportunity to take a look at quite a number of study designs and protocols. Even though the formal comment period for that closed in January 1991, we have not completed all the revisions. This is going to be a project that will probably take somewhere between 2 and 5 yr.
There were 2 reasons why we chose to make that particular request at that particular time. First, we were responding to a Congressional mandate of the fall of 1988, which directs the EPA to reregister between now and 1997 every pesticide initially registered before November 1, 1984. This equates to a sizable number of active ingredients and many thousands of products. Second, we are currently revising Part 158 of the Code of Federal Regulations (1). Embodied in Part 15 8 are the data requirements with respect to a particular use of a pesticide. My personal opinion is that as we revise these requirements it is reasonable in both a scientific and a regulatory sense to have any data requested be state of the art, as opposed to being in the context of existing guidelines that were written and published in 1984. In many of our subdisciplines, significant advancement has been made in the state of our knowledge, and it should be reflected in the kinds of data that we ask for and following that, in the ways that we interpret that information. This is our intent in revising the requirements. Table I presents our requirements with respect to clinical pathology for chronic studies. As the table indicates our current requirements do not ask for every hematology endpoint. The current requirements mention 17 specific clinical chemistry tests in the guidelines, depending on the study type. The table focuses on requirements for chronic studies, because it tends to be under those conditions that the highest number of parameters are requested, as opposed to some of the other study types where little or none might be. One might have a somewhat similar set for the subchronic studies in certain circumstances. For pesticide registration, subchronic studies are not always run before the chronic studies. We only require a range-finding study to establish the maximum tolerated dose, and that study is not necessarily as long as 13 weeks. I would like to stress, and I think I speak for most scientists in the regulatory agencies, that the tests presented in Table I are guidelines; they are not test standards. It is often very helpful to initiate a dialog directly between the scientists in the regulatory agencies and the scientists in the regulated community to resolve these issues. We do encourage, and often have, conversations directly with scientists both in the testing laboratories and in the sponsoring organization.
One of the things I found troublesome in the response to our call for comments on Subpart F in the Federal Register was the paucity of comments received on clinical pathology tests, particularly for chronic studies. This is in direct contrast to the input I have received from scientists at this meeting. Obviously the clinical pathologists and clinical biochemists have a special interest in this area, rather than a more general toxicological interest, but the comments we have received do not reflect your interest. For instance, we received only 6 comments on our guidelines for chronic feeding studies or the combined chronic toxicity/oncogenicity studies that are usually done in the rat and the chronic nonrodent studies. These 6 comments included 3 companies, 1 testing laboratory, a major trade association, and a consulting firm that does work on behalf of a number of the registrants. The following were the only recommendations with respect to clinical pathology in these 3 study types: 7. Include another method for preventing bacterial growth in urine samples.
I would like to comment on the need for urinalysis. Our guidelines require urinalysis for chronic studies only if there is an indication that the test substance may have an effect on some aspect of the urinary system. At the current meeting, I have heard many more comments, including many questions raised about the requirement for omithine decarboxylase. This may be one we should reconsider based on the input of the scientists at this meeting. It is my perception that the clinical pathologists and clinical biochemists involved in performing and interpreting these tests would have many more useful comments on these guidelines, and I would be most interested in receiving their input.
